Resistance to Chemotherapy in Breast Cancer: Potential role of p21B, p27 and the p53 apoptotic pathway
Has parts
Paper I: PLoS ONE 3(8), Chrisanthar, R.; Knappskog, S.; Løkkevik, E.; Anker, G.; Østenstad, B.; Lundgren, S.; Berge, E. O.; Risberg, T.; Mjaaland, I.; Mæhle, L.; Engebretsen, L. F.; Lillehaug, J. R.; Lønning, P. E., CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer, e3062. Copyright 2008 Chrisanthar et al. Published by Public Library of Science. Reproduced with permission. Published version. The published version is also available at: http://dx.doi.org/10.1371/journal.pone.0003062Paper II: Chrisanthar, R.; Knappskog, S.; Løkkevik, E.; Geisler, J.; Østenstad, B.; Lundgren, S.; Risberg, T.; Mjaaland, I.; Lillehaug, J. R.; Lønning, P. E., 2009, Neither mutations in the p27 gene nor its Val109Gly polymorphism is associated with lack of response to epirubicin or paclitaxel in locally advanced breast cancer. Full text not available in BORA.
Paper III: International journal of cancer 121(4), Knappskog, S.; Chrisanthar, R.; Staalesen, V.; Børresen-Dale, A. L.; Gram, I. T.; Lillehaug, J. R.; Lønning, P.E., Mutations and polymorphisms of the p21B transcript in breast cancer, pp. 908-910. Copyright 2007 Wiley-Liss, Inc. Full text not available in BORA due to publisher restrictions. The published version is available at: http://dx.doi.org/10.1002/ijc.22777